CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Clinical trials for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) explained in plain language.
Never miss a new study
Get alerted when new CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) trials appear
Sign up with your email to follow new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug tested for rare 'Cold Allergy' disease
Disease control Recruiting nowThis early-stage study is testing a new drug called JTE-162 for people with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare genetic inflammatory disease. The study will check if the drug is safe and if it reduces inflammation and symptoms like rash, joint pain, and fever. O…
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Phase: PHASE1 • Sponsor: Akros Pharma Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Real-World watch: tracking a drug for rare, debilitating fevers
Disease control Recruiting nowThis study aims to monitor the safety and effectiveness of the drug Ilaris (canakinumab) in real-world clinical settings. It will include children and adults with rare hereditary fever syndromes or a form of juvenile arthritis who are already receiving the drug as part of their s…
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC